Back

Title
  • en Pretreatment of Hepatocyte Growth Factor Gene Transfer Mediated by Octaarginine Peptide-Modified Nanoparticles Ameliorates LPS/D-Galactosamine-Induced Hepatitis
Creator
Accessrights open access
Rights
  • en This is a copy of an article published in the Nucleic Acid Therapeutics © 2012 copyright Mary Ann Liebert, Inc.; Nucleic Acid Therapeutics is available online at: http://online.liebertpub.com.
Subject
  • NDC 499
Description
  • Abstract en We previously reported that an octaarginine- and pH-sensitive fusogenic peptide-modified multifunctional envelope-type nano device (R8-GALA-MEND) produces a high level of gene expression in the liver. In this study, we report on an examination of whether this gene delivery system exerts potent hepatoprotective effects against lipopolysaccharide/D-galactosamine (LPS/D-GalN)-induced acute liver injury. In vivo-jetPEI^[TM]-Gal, a commercially available in vivo transfection reagent, was used as a reference. The systemic administration of the R8-GALA-MEND or in vivo-jetPEI^[TM]-Gal showed that the latter was more toxic than the R8-GALA-MEND, indicating that R8-GALA-MEND is a safer system than in vivo-jetPEI^[TM]-Gal. Pretreatment with R8-GALA-MEND or in vivo-jetPEI^[TM]-Gal loaded with hepatocyte growth factor (HGF) pDNA inhibited serum GPT and GOT levels from becoming elevated. However, the survival rate of the mice was significantly enhanced in the case of R8-GALA-MEND, but not for the in vivo-jetPEI^[TM]-Gal treatment. These results demonstrate that R8-GALA-MEND has the potential for use in the pretreatment of an acute liver injury.
Publisher en Mary Ann Liebert
Date
    Issued2012-10-02
Language
  • eng
Resource Type journal article
Version Type VoR
Identifier HDL http://hdl.handle.net/2115/50423
Relation
  • isIdenticalTo DOI https://doi.org/10.1089/nat.2012.0352
Journal
    • PISSN 2159-3337
      • en Nucleic Acid Therapeutics
      • Volume Number22 Issue Number5 Page Start360 Page End363
File
Oaidate 2023-07-26